GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » Shiller PE Ratio

Summit Therapeutics (Summit Therapeutics) Shiller PE Ratio : (As of May. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Summit Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Summit Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Shiller PE Ratio Chart

Summit Therapeutics Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Summit Therapeutics Quarterly Data
Jan19 Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Summit Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Summit Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Summit Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Summit Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Summit Therapeutics's Shiller PE Ratio falls into.



Summit Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Summit Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Summit Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.01/129.4194*129.4194
=-0.010

Current CPI (Dec. 2023) = 129.4194.

Summit Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201401 -0.815 98.692 -1.069
201404 -0.135 100.023 -0.175
201407 -0.135 100.520 -0.174
201410 -0.096 100.176 -0.124
201501 -0.105 98.604 -0.138
201504 -0.093 99.824 -0.121
201507 -0.109 100.691 -0.140
201510 -0.139 100.346 -0.179
201601 -0.114 99.957 -0.148
201604 -0.132 100.947 -0.169
201607 -0.691 101.524 -0.881
201610 -0.098 101.988 -0.124
201701 -0.100 102.456 -0.126
201704 -0.103 103.167 -0.129
201707 -0.066 103.278 -0.083
201710 -0.013 104.070 -0.016
201801 -0.226 104.578 -0.280
201804 -0.110 105.708 -0.135
201807 0.420 106.324 0.511
201810 -0.127 106.695 -0.154
201901 -0.066 106.200 -0.080
201904 -0.039 107.818 -0.047
201907 -0.036 108.250 -0.043
201910 -0.052 108.577 -0.062
202003 -0.091 108.902 -0.108
202006 -0.230 108.767 -0.274
202009 -0.260 109.815 -0.306
202012 -0.180 109.897 -0.212
202103 -0.210 111.754 -0.243
202106 -0.270 114.631 -0.305
202109 -0.200 115.734 -0.224
202112 -0.280 117.630 -0.308
202203 -0.150 121.301 -0.160
202206 -0.120 125.017 -0.124
202209 -0.100 125.227 -0.103
202212 -0.040 125.222 -0.041
202303 -1.430 127.348 -1.453
202306 -0.020 128.729 -0.020
202309 -0.030 129.860 -0.030
202312 -0.010 129.419 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Summit Therapeutics  (NAS:SMMT) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Summit Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Summit Therapeutics (Summit Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Executives
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh director 51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan director, 10 percent owner, officer: See Remarks 611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia director 6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark director C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian officer: VP, Corporate Controller C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell officer: Chief Scientific Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham officer: Chief Clinical Affairs Officer ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov director, officer: See Remarks ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142

Summit Therapeutics (Summit Therapeutics) Headlines

From GuruFocus

Summit Therapeutics Inc. Investors: Company Investigated by the Portnoy Law Firm

By Stock market mentor Stock market mentor 02-08-2023

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

By Business Wire Business Wire 03-03-2023